VERA Stock Price | Vera Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Vera Therapeutics Inc • VERA

VERA current price

$42.34+165.79%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

+1.12%

-9.08%

-7.27%

+22.16%

+165.79%

MAX

+268.17%

About Vera Therapeutics Inc

Ticker

VERA

Trading on

NASDAQ

ISIN

US92337R1014

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Marshall W. Fordyce M.D.

Headquarters

8000 Marina Boulevard, Brisbane, CA, United States, 94005

Employees

Website

https://veratx.com

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Metrics

BasicAdvanced

Market cap

$2.65B

P/E ratio

EPS

-$2.61

Dividend Yield

0.00%

Beta

1.03

Forward P/E ratio

EBIDTA

$-90.7M

Ex dividend date

Price & volume

Market cap

$2.65B

Average daily volume

0.5M

90-day return

-7.27%

30-day return

-9.08%

7-day return

1.12%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

9.27

Earnings

EPS

-$2.61

EPS estimate (current quarter)

-$0.66

EPS estimate (next quarter)

-$0.69

EBITDA

$-90.7M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.03

52-week High

$51.61

52-week Low

$14.20

50-day moving average

$45.14

200-day moving average

$40.77

Short ratio

6.81

Short %

13.73%

Management effectiveness

ROE (TTM)

65.11%

ROA (TTM)

33.37%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

63.3M

Float

51.5M

Insiders %

6.83%

Institutions %

94.68%

Analyst Insights & forecasts

92% Buy

8% Hold

0% Sell

Based on information from 12 analysts.

Average price target

$64.58

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.60

-$0.51

17.65%

Q4 • 23Beat

-$0.56

-$0.53

5.66%

Q1 • 24Beat

-$0.62

-$0.56

10.71%

Q2 • 24Beat

-$0.85

-$0.61

38.73%

Q3 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-33.7M

∞%

Q2 • 24

$0M

$-46.6M

∞%

Q3 • 24

NaN%

38.34%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$397M

$69.4M

17.47%

Q2 • 24

$369M

$79.5M

21.57%

Q3 • 24

7.23%

14.52%

23.45%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-24.8M

$-22.7M

$3.4M

$-24.8M

Q2 • 24

$-36.9M

$38.3M

$0.7M

$-62M

Q3 • 24

48.84%

268.97%

78.51%

150.16%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Vera Therapeutics Inc share?

Vera Therapeutics Inc shares are currently traded for $42.34 per share.

How many shares does Vera Therapeutics Inc have?

Vera Therapeutics Inc currently has 63.3M shares.

Does Vera Therapeutics Inc pay dividends?

No, Vera Therapeutics Inc doesn't pay dividends.

What is Vera Therapeutics Inc 52 week high?

Vera Therapeutics Inc 52 week high is $51.61.

What is Vera Therapeutics Inc 52 week low?

Vera Therapeutics Inc 52 week low is $14.20.

What is the 200-day moving average of Vera Therapeutics Inc?

Vera Therapeutics Inc 200-day moving average is $40.77.

Who is Vera Therapeutics Inc CEO?

The CEO of Vera Therapeutics Inc is Dr. Marshall W. Fordyce M.D..

How many employees Vera Therapeutics Inc has?

Vera Therapeutics Inc has 82 employees.

What is the market cap of Vera Therapeutics Inc?

The market cap of Vera Therapeutics Inc is $2.65B.

What is the P/E of Vera Therapeutics Inc?

The current P/E of Vera Therapeutics Inc is null.

What is the EPS of Vera Therapeutics Inc?

The EPS of Vera Therapeutics Inc is -$2.61.

What is the PEG Ratio of Vera Therapeutics Inc?

The PEG Ration of Vera Therapeutics Inc is null.

What do analysts say about Vera Therapeutics Inc?

According to the analysts Vera Therapeutics Inc is considered a buy.

Vera Therapeutics Inc news

thumbs_up_down

•Neutral

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares of Class A common stock and restricted stock units (RSUs) for 86,625 shares of Class A common stock to seventeen new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire•09 Dec 2024, 23:29

thumbs_up_down

•Neutral

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera's new Chief Legal Officer, under Vera's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire•22 Nov 2024, 21:05

thumbs_up_down

•Neutral

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire•11 Nov 2024, 21:05